Teva Lowers 2026 Non-GAAP Operating Profit Outlook On Emalex Deal; On Track To Achieve 2027 Targets
29/4 14:08
(RTTNews) - Teva Pharmaceutical Industries (TEVA) said, for 2026, non-GAAP operating income is now projected in a range of $3.80 - $4.0 billion, revised from $4.55 - $4.8 billion stand-alone outlook, impacted by an expected $700 million IPR&D charge and $75 million to reflect Ema...